INVESTIGATION OF FORCED DEGRADATION PRODUCTS OF ETODOLAC BY LC AND LC-MS/MS
Keywords:
Etodolac, Forced degradation studies, Degradation products, LC, LC-MSMSAbstract
Objective: The main objective of this study was to investigate the degradation products (DPs) of Etodolac (ETD) API under different stress conditions (acid hydrolysis, base hydrolysis, oxidation, thermal and photolysis) and to characterize the major DPs using Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) and Infrared (IR) spectroscopy.
Methods: The proposed study describes a reversed-phase LC and LC-MS/MS method. Separation of ETD and its DPs was achieved on a Phenomenex C18 column. Structures of the major DPs were studied using a Triple Quadrupole Mass Spectrometer. A separate gradient LC-MS/MS method was developed for this purpose. The analysis was done using Shim-pack XR ODS column. Possible chemical reactions were predicted depending on the degradation type and the fragmentation data obtained from LC-MS/MS. Major DPs were isolated using preparative LC technique. These DPs were obtained in solid form using rotavap and lyophilizer and were then analyzed by IR spectroscopy to confirm their structural details.
Results: ETD was found to degrade completely under acid hydrolysis; it degraded 68 % under oxidation, 25 % after photolysis, 6 % in basic conditions and less than 1 % in thermal degradation. Four major DPs were characterized using LC-MS/MS and IR spectroscopy.
Conclusion: The DPs of ETD were investigated and characterized. Also, the tentative degradation pathways of ETD under different stress conditions were postulated.
Keywords: Etodolac, Forced degradation studies, Degradation products, LC, LC-MS/MSÂ
Downloads
References
Dirk BS, Gottfried B. Isolation of an unknown metabolite of the non-steroidal anti-inflammatory drug Etodolac and its identification as 5-hydroxy Etodolac. J Pharm Biomed Anal 2001;25:977-84.
Dirk BS, Chankvetadze B, Blaschke G, Claudia D, Salvatore F. Separation and identification of Etodolac and its urinary phase I metabolites using capillary electrochromatography and on-line capillary electrochromatography–electrospray ionization mass spectrometry coupling. J Chromatogr A 2000;887:393-407.
Mohammed R, Abyazani K, Esaw B. Etodolac in equine urine and serum: Determination by high-performance liquid chromatography with ultraviolet detection, confirmation, and metabolite identification by atmospheric pressure ionization mass spectrometry. J Anal Toxicol 1999;23:200-9.
ICH guidelines Q1A (R2). Stability testing of new drug substances and products. International Conference on Harmonization; 2003.
Saxena D, Damale S, Joshi A, Datar A. Forced degradation studies of Amlodipine Besylate and characterization of its major degradation products by LC-MS/MS. Int J Life Sci Biotechnol Pharm Res 2014;3:196-207.
Aneesh TP, Rajasekaran A. Forced degradation studies–A tool for determination of stability in pharmaceutical dosage forms. Int J Biol Pharm Res 2012;3:699-702.
Abela D, Schembri, Farrugia C. A chromatographic determination of the stability of solutions of Amlodipine Benazepril and Amlodipine Besilate. Presented at the seventh world meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Malta; 2010.
Murakami T, Fukutsu N, Kondo J, Takao K, Fumiyo K. Application of liquid chromatography-two-dimensional nuclear magnetic resonance spectroscopy using pre-concentration column trapping and liquid chromatography-mass spectrometry for the identification of degradation products in stressed commercial Amlodipine maleate tablets. J Chromatogr A 2008;118:67-76.
Singh S, Bakshi M. Guidance on the conduct of stress tests to determine the inherent stability of drugs. Pharmaceutical Technology Online; 2000. Available from: www.pharmaportal.com. [Last accessed on 10 Dec 2015].
Patel RM, Patel PM, Patel NM. Stability indicating HPLC method development-a review. Int J Pharm Res 2011;2:79-87.
Singh R, Rehman Z. Current trends in forced degradation study for pharmaceutical product development. J Pharm Edu Res 2012;3:54-93.
Hotha KK, Reddy SPK, Raju K, Ravindranath LK. Forced degradation studies: Practical approach-Overview of regulatory guidance and literature for the drug products and drug substances. Int J Pharm Res 2013;4:78-85.
Ngwa G. Forced degradation as an integral part of HPLC stability-indicating method development. Drug Delivery Technol 2010;10:1-4.
Brummer H. How to approach a forced degradation study. Life Sci Technical Bull 2011;31:1-4.
Patel MJ, Patel AN, Patel CN, Badmanaban R. A simple and sensitive HPTLC method for simultaneous analysis of Tolperisone hydrochloride and Etodolac in combined fixed-dose oral solid formulation. J Planar Chromatography modern TLC 2012;25:85-8.
Kulkarni VG, Gandhi SV, Deshpande PB, Devikar P. High-performance thin layer chromatographic analysis of Paracetamol and Etodolac in combined tablet dosage form. J Chem Pharm Res 2012;4:1750-5.
Chaube PH, Gandhi SV, Deshpande PB, Kulkarni VG. High-performance thin layer chromatographic analysis of Paracetamol and Etodolac in spiked human plasma. J Pharm Biomed Sci 2010;7:1-6.
Palandhe AJ, Jadhav SB, Tapkir AS, Chaudhari PD, Survase BH, Rachamale PM. Development and validation of stability indicating assay method of etodolac by using UV-Vis spectrophotometer. Int J Pharm Chem Sci 2013;2:678-85.
Badmanaban R, Patel MJ, Patel CN. Simultaneous analysis of Tolperisone hydrochloride and Etodolac in combined fixed oral dosage formulation by spectrophotometry. Res J Pharm Technol 2011;4:124-9.
Thankappan S, Parmar A, Sailor B. Development and validation of a spectroscopic method for simultaneous estimation of Etodolac and Thiocolchicoside in tablet formulation. J Pharm Res 2012;5:3004-7.
Gouda AA, Hassan WS. Spectrophotometric determination of Etodolac in pure form and pharmaceutical formulations. Chem Cent J 2008;2:1-8.
Patidar R, Baghel US, Patela S, Singhal M, Patidara N, Englaa G, et al. Simultaneous spectrophotometric estimation of Paracetamol and Etodolac in tablet dosage forms. J Global Pharma Technol 2009;1:62-6.
Thankappan S, Parmar A, Sailor B, Vekariya K, Shah D. Simultaneous estimation of Etodolac and Thiocolchicoside by UV spectrophotometric method in tablet formulation. Int J Pharma Innovation 2010;2:192-200.
Srinivas G, Vidhyadhara S, Ramanaiah G, Srilakshmi V. Method development and validation of stability indicating RP-HPLC method for simultaneous estimation of Tolperisone HCl and Etodolac in bulk and its pharmaceutical formulations. Int J Bioassays 2014;3:2045-52.
Sruthi A, Thanuja N, Sai SM, Sudheer KD, Sreekanth G. A simple RP-HPLC method for simultaneous estimation of Paracetamol and Etodolac in tablet dosage form. Indo Am J Pharm Res 2013;3:3742-51.
Balan P, Kannappan N. Development and validation of stability indicating RP-UPLC method for simultaneous estimation of Etodolac and Paracetamol in combined dosage form. J Sci Res Pharm 2014;3:33-7.
Lee HS, Kang IlM, Lee HW, Seo JH, Ryu JH, Choi SJ, et al. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry for the determination of Etodolac in human plasma. J Chromatogr B 2008;863:158-62.
ICH guidelines Q1B. Stability testing: photostability testing of new drug substances and products. International Conference on Harmonization; 1996.
Patel A, Shah B. RP-HPLC method development, and validation using the factorial design for simultaneous estimation of Thiocolchicoside and Etodolac with forced degradation studies. J Pharma Sci Biosci Res 2014;4:374-82.
Rajput M, Hamid H, Aggarwal M, Khandal RK. Development and validation of a stability indicating reverse phase HPLC method for simultaneous determination of Etodolac and Paracetamol in its tablet dosage formulation. Int J Innovation Res Sci Eng Technol 2015;4:19074-86.
Pandey R, Patil PO, Bari SB, Dhumal DM. Simultaneous estimation of Etodolac and Thiocolchicoside in bulk and in tablet formulation by UV spectrophotometry. Chem Ind Chem Eng Q 2014;20:9-17.
Saleh OA, El-Azzouny AA, Aboul-Enein HY, Badawey AM, Rashed MS. Development and validation of stability-indicating HPLC and DD1-spectrophotometric assays of Etodolac in bulk form and in pharmaceutical dosage form. J Liq Chromatogr Relat Technol 2009;32:2584-99.
Lee YJ, Padula J, Lee HK. Kinetics and mechanisms of Etodolac degradation in aqueous solutions. J Chromatogr B 1988;77:81-6.
Barakat NS. Etodolac-liquid-filled dispersion into hard gelatin capsules: An approach to improve dissolution and stability of Etodolac formulation. Drug Design Discovery 2009;32:865-76.
Pilli R, Nagabhushanam MV, Kiran KS. Etodolac dissolution improvement by preparation of solid dispersions with cyclodextrin complexes. Int J Pharm Sci Res 2014;5:4774-91.